Wall Street analysts expect Teva Pharmaceutical Industries Ltd. (TEVA) to post quarterly earnings of $0.75 per share in its upcoming report, which indicates a year-over-year increase of 5.6%. Revenues are expected to be $3.96 billion, up 2% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.In addition to the Zacks Rank ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) J.P. Morgan 42nd Annual Global Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Richard Francis - President, CEO & Director Conference Call Participants Christopher Schott - JPMorgan Christopher Schott Good morning, everybody. I'm Chris Schott, Firm Analyst at JPMorgan and it's my pleasure to be introducing Teva today. From the company we have CEO, Richard Francis. Richard joined Teva roughly a year ago, can be said a very productive 2 ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) J.P. Morgan 42nd Annual Global Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Richard Francis - President, CEO & Director Conference Call Participants Christopher Schott - JPMorgan Christopher Schott Good morning, everybody. I'm Chris Schott, Firm Analyst at JPMorgan and it's my pleasure to be introducing Teva today. From the company we have CEO, Richard Francis. Richard joined Teva roughly a year ago, can be said a very productive 2 ...

About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

Corcept Therapeutics Inc. shares CORT, -1.22% dropped 32% premarket on Tuesday after a federal court in New Jersey on Friday ruled against the drugmaker in its patent infringement lawsuit against Teva Pharmaceutical Industries Ltd. TEVA, -0.29%. Teva seeks to market a generic version of Corcept’s Korlym, a treatment for the endocrine disorder Cushing’s syndrome, but Corcept failed to demonstrate that there is a likely direct infringement of its patent claims for the drug, the court said in its opinion. “Th ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast wil ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 8:20 AM ET Company Participants Richard Francis - President and Chief Executive Officer Eric Hughes - Executive Vice President, Global R&D and Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Excellent. Well listen, thank you guys for joining us. Pleasure to have the new Teva management on the new Teva story, hopefully. So looking forward to this discuss ...

Financial Data and Key Metrics Changes - The company's net debt at the end of Q3 2023 was $17.7 billion, down from $18.4 billion at the end of 2022, while gross debt decreased to $20 billion from $21.2 billion [1] - The net debt-to-EBITDA ratio improved to 4.03x for Q3 2023, attributed to foreign exchange rate movements and free cash flow generation [1] - Non-GAAP revenue for Q3 2023 was approximately $3.9 billion, representing a 7% increase compared to Q3 2022 [7][29] - Non-GAAP gross profit margin improved to 53.5% in Q3 2023 from 53% in Q3 2022, driven by a favorable product mix [8] - Non-GAAP operating margin decreased to 26.5% in Q3 2023 from 27.2% in Q3 2022, primarily due to increased R&D expenses [9] Business Line Data and Key Metrics Changes - Revenue from AUSTEDO grew by 30% in Q3 2023, reaching $339 million, while AJOVY saw a 22% increase in revenue to $114 million [56][66] - The generics business in North America experienced a 15% revenue increase in Q3 2023, driven by higher sales of generic products [30] - The Europe segment's revenue remained flat in local currency terms, with strong growth in AJOVY offset by lower revenues from legacy brands [30] Market Data and Key Metrics Changes - Revenues from international markets increased by 20% in local currency terms, mainly due to higher revenue from generic products [31] - Approximately 46% of Q3 2023 revenue came from sales denominated in non-US dollar currencies, with foreign exchange rate movements negatively impacting revenues [21] Company Strategy and Development Direction - The company is focused on its "Pivot to Growth" strategy, emphasizing innovation and expanding its product pipeline, particularly in the generics and biosimilars markets [60][32] - A partnership with Sanofi was announced to advance the TL1A asset, which is seen as a significant growth opportunity [61][37] - The company aims to achieve a long-term financial target of a 2x net debt-to-EBITDA ratio by the end of 2027 [1] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate market conditions and emphasized the importance of maintaining a competitive edge through R&D and product innovation [23][32] - The company is reframing its 2023 free cash flow guidance to a range of $1.7 billion to $2.1 billion, anticipating a sequential ramp-up in revenue and profitability [11] - Management acknowledged the impact of inflationary pressures but noted improvements in gross margins due to a favorable product mix [8][78] Other Important Information - The company reported a GAAP income of $80 million in Q3 2023, compared to $56 million in Q3 2022, primarily due to reduced tax expenses [20] - The company is actively seeking business development opportunities and licensing to expand its pipeline [12] Q&A Session Summary Question: Is the company comfortable with its current position or actively seeking to expand its pipeline? - Management confirmed that they are actively looking to expand their pipeline through business development and licensing opportunities [12] Question: Is there an expectation of large one-offs impacting guidance? - Management maintained guidance for AUSTEDO and noted that there are no significant changes expected in revenue lines, considering the seasonality of Q4 [5] Question: What is the status of the TL1A partnership and the $600 million milestone? - Management indicated that the partnership with Sanofi is progressing well and that the milestone is contingent on demonstrating competitive data [13][87] Question: What are the expectations for R&D expenses in Q4? - Management stated that R&D expenses are expected to remain elevated as part of their strategy to advance their innovative pipeline [16][90] Question: How does the company view the market conditions for generics? - Management acknowledged that market conditions are influenced by supply, demand, and competition, and emphasized the importance of timely product delivery to mitigate pricing pressures [23]